Signalling, cell cycle and pluripotency in embryonic stem cells

Trends in Cell Biology

Volumn 12, Issue 9, 2002, Pages 432-438

  Burdon, Tom ^a   Smith, Austin ^b   Savatier, Pierre ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN E; GLYCOPROTEIN GP 130; JANUS KINASE; LEUKEMIA INHIBITORY FACTOR; LEUKEMIA INHIBITORY FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; RETINOBLASTOMA PROTEIN; SERUM RESPONSE FACTOR; STAT3 PROTEIN;

BINDING SITE; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL RENEWAL; DIMERIZATION; EMBRYO CELL; ENZYME ACTIVITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTIGENS, CD; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; CYCLINS; CYTOKINE RECEPTOR GP130; DNA-BINDING PROTEINS; EMBRYO; GROWTH INHIBITORS; HUMANS; INTERLEUKIN-6; LEUKEMIA INHIBITORY FACTOR; LYMPHOKINES; MEMBRANE GLYCOPROTEINS; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, BIOLOGICAL; PLURIPOTENT STEM CELLS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

JANUS;

EID: 0036709213     PISSN: 09628924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0962-8924(02)02352-8     Document Type: Review

References (70)

1. Gardner R.L., Brook F.A. Reflections on the biology of embryonic stem cells. Int. J. Dev. Biol. 41:1997;235-243.
2. Nichols J. Introducing embryonic stem cells. Curr. Biol. 11:2001;R503-R505.
3. Smith A. Embryonic stem cells. Marshak D.R., et al. Stem Cell Biology. 2001;205-230 Cold Spring Harbor Laboratory Press.
4. Beddington R.S.P., Robertson E.J. An assessment of the developmental potential of embryonic stem cells in the midgestation mouse embryo. Development. 105:1989;733-737.
5. Bradley A., et al. Modifying the mouse: design and desire. Biotechnology. 10:1992;534-539.
6. Doetschman T.C., et al. The in vitro development of blastocyst-derived embryonic stem cell lines: formation of visceral yolk sac, blood islands and myocardium. J. Embryol. Exp. Morphol. 87:1985;27-45.
7. Keller G.M. In vitro differentiation of embryonic stem cells. Curr. Opin. Cell Biol. 7:1995;862-869.
8. Thomson J.A., et al. Embryonic stem cell lines derived from human blastocysts. Science. 282:1998;1145-1147.
9. Savatier P., et al. Contrasting patterns of retinoblastoma protein expression in mouse embryonic stem cells and embryonic fibroblasts. Oncogene. 9:1994;809-818.
10. Savatier P., et al. Withdrawal of differentiation inhibitory activity/leukemia inhibitory factor up-regulates D-type cyclins and cyclin-dependent kinase inhibitors in mouse embryonic stem cells. Oncogene. 12:1996;309-322.
11. Smith A.G. Embryo-derived stem cells: of mice and men. Annu. Rev. Cell Dev. Biol. 17:2001;435-462.
12. Suda Y., et al. Mouse embryonic stem cells exhibit indefinite proliferative potential. J. Cell Physiol. 133:1987;197-201.
13. Smith A.G., et al. Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides. Nature. 336:1988;688-690.
14. Williams R.L., et al. Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells. Nature. 336:1988;684-687.
15. Yoshida K., et al. Maintenance of the pluripotential phenotype of embryonic stem cells through direct activation of gp130 signalling pathways. Mech. Dev. 45:1994;163-171.
16. Rathjen P.D., et al. Differentiation inhibiting activity is produced in matrix-associated and diffusible forms that are generated by alternate promoter usage. Cell. 62:1990;1105-1114.
17. Stewart C.L., et al. Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. Nature. 359:1992;76-79.
18. Davis S., et al. LIFRβ and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor. Science. 260:1993;1805-1808.
19. Niwa H., et al. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev. 12:1998;2048-2060.
20. Ernst M., et al. The carboxyl-terminal domains of gp130-related cytokine receptors are necessary for suppressing embryonic stem cell differentiation. Involvement of STAT3. J. Biol. Chem. 274:1999;9729-9737.
21. Boeuf H., et al. Leukemia inhibitory factor-dependent transcriptional activation in embryonic stem cells. J. Cell Biol. 138:1997;1207-1217.
22. Matsuda T., et al. STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells. EMBO J. 18:1999;4261-4269.
23. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem. J. 351:2000;289-305.
24. Hibi M., Hirano T. Gab-family adapter molecules in signal transduction of cytokine and growth factor receptors, and T and B cell antigen receptors. Leuk. Lymphoma. 37:2000;299-307.
25. Burdon T., et al. Suppression of SHP-2 and ERK signalling promotes self-renewal of mouse embryonic stem cells. Dev. Biol. 210:1999;30-43.
26. Schmitz J., et al. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J. Biol. Chem. 275:2000;12848-12856.
27. Cheng A.M., et al. Mammalian Grb2 regulates multiple steps in embryonic development and malignant transformation. Cell. 95:1998;793-803.
28. Qu C.K., Feng G.S. Shp-2 has a positive regulatory role in ES cell differentiation and proliferation. Oncogene. 17:1998;433-439.
29. Burdon T., et al. Signalling mechanisms regulating self-renewal and differentiation of pluripotent embryonic stem cells. Cells Tissues Organs. 165:1999;131-143.
30. Vanhaesebroeck B., Alessi D.R. The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J. 346:2000;561-576.
31. Sun H., et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc. Natl Acad. Sci. U. S. A. 96:1999;6199-6204.
32. Williams M.R., et al. The role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in embryonic stem cells. Curr. Biol. 10:2000;439-448.
33. Kobayashi T., Cohen P. Activation of serum- and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2. Biochem. J. 339:1999;319-328.
34. Park J., et al. Serum and glucocorticoid-inducible kinase (SGK) is a target of the PI3-kinase-stimulated signaling pathway. EMBO J. 18:1999;3024-3033.
35. Tu Z., et al. Embryonic and hematopoietic stem cells express a novel SH2-containing inositol 5'-phosphatase isoform that partners with the Grb2 adapter protein. Blood. 98:2001;2028-2038.
36. Harbour J.W., Dean D.C. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev. 14:2000;2393-2409.
37. Harbour J.W., et al. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell. 98:1999;859-869.
38. Bartek J., Lukas J. Pathways governing G1/S transition and their response to DNA damage. FEBS Lett. 490:2001;117-122.
39. Bartkova J., et al. Aberrations of the G1- and G1/S-regulating genes in human cancer. Prog. Cell Cycle Res. 3:1997;211-220.
40. Sherr C.J. Cancer cell cycles. Science. 274:1996;1672-1677.
41. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1999;1501-1512.
42. Robanus-Maandag E., et al. p107 is a suppressor of retinoblastoma development in pRb-deficient mice. Genes Dev. 12:1998;1599-1609.
43. LeCouter J.E., et al. Cloning and expression of the Rb-related mouse p130 mRNA. Oncogene. 12:1996;1433-1440.
44. Lukas J., et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature. 375:1995;503-506.
45. ink4 requires functional retinoblastoma protein. Proc. Natl Acad. Sci. U. S. A. 92:1995;6289-6293.
46. Dannenberg J.H., et al. Ablation of the retinoblastoma gene family deregulates G(1) control causing immortalization and increased cell turnover under growth-restricting conditions. Genes Dev. 14:2000;3051-3064.
47. Sage J., et al. Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Genes Dev. 14:2000;3037-3050.
48. St Croix B., et al. E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J. Cell Biol. 142:1998;557-571.
49. Brown J.P., et al. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science. 277:1997;831-834.
50. Aladjem M.I., et al. ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage. Curr. Biol. 8:1998;145-155.
51. Prost S., et al. p53-independent DNA repair and cell cycle arrest in embryonic stem cells. FEBS Lett. 425:1998;499-504.
52. Donnellan R., Chetty R. Cyclin E in human cancers. FASEB J. 13:1999;773-780.
53. Hall M., Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res. 68:1996;67-108.
54. Wianny F., et al. G1-phase regulators, cyclin D1, cyclin D2, and cyclin D3: up-regulation at gastrulation and dynamic expression during neurulation. Dev. Dyn. 212:1998;49-62.
55. Lavoie J.N., et al. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J. Biol. Chem. 271:1996;20608-20616.
56. Albanese C., et al. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J. Biol. Chem. 270:1995;23589-23597.
57. Winston J.T., et al. Regulation of the cell cycle machinery by oncogenic ras. Oncogene. 12:1996;127-134.
58. Jirmanova, L. et al. (2002) Differential contributions of ERK and PI3-kinase to the regulation of cyclin D1 expression and to the control of the G1/S transition in mouse embryonic stem cells. Oncogene (in press)
59. Diehl J.A., et al. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12:1998;3499-3511.
60. Fang F., et al. Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science. 271:1996;499-502.
61. Fukada T., et al. STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition. EMBO J. 17:1998;6670-6677.
62. Shirogane T., et al. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity. 11:1999;709-719.
63. Badache A., Hynes N.E. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res. 61:2001;383-391.
64. Novitch B.G., et al. pRb is required for MEF2-dependent gene expression as well as cell- cycle arrest during skeletal muscle differentiation. Curr. Biol. 9:1999;449-459.
65. Gu W., et al. Interaction of myogenic factors and the retinoblastoma protein mediates muscle cell commitment and differentiation. Cell. 72:1993;309-324.
66. Chen P.L., et al. Retinoblastoma protein directly interacts with and activates the transcription factor NF-IL6. Proc. Natl Acad. Sci. U. S. A. 93:1996;465-469.
67. Chen P.L., et al. Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/EBPs. Genes Dev. 10:1996;2794-2804.
68. Thomson J.A., et al. Isolation of a primate embryonic stem cell line. Proc. Natl Acad. Sci. U. S. A. 92:1995;7844-7848.
69. Shamblott M.J., et al. Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc. Natl Acad. Sci. U. S. A. 95:1998;13726-13731.
70. Reubinoff B.E., et al. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat. Biotechnol. 18:2000;399-404.